首页> 外文会议>Conference on Oral-Based Diagnostics >Oral Fluid-Based Biomarkers of Alveolar Bone Loss in Periodontitis
【24h】

Oral Fluid-Based Biomarkers of Alveolar Bone Loss in Periodontitis

机译:牙周炎肺泡骨质损失的口腔液体生物标志物

获取原文

摘要

Periodontaldisease is a bacteria-induced chronic inflammatory disease affecting the soft and hard supporting structures encompassing the teeth. When left untreated, the ultimate outcome is alveolar bone loss and exfoliation of the involved teeth. Traditional periodontal diagnostic methods include assessment of clinical parameters and radiographs. Though efficient, these conventional techniques are inherently limited in that only a historical perspective, not current appraisal, of disease status can be determined. Advances in the use of oral fluids as possible biological samples for objective measures of current disease state, treatment monitoring, and prognostic indicators have boosted,saliva and other oral-based fluids to the forefront of technology. Oral fluids contain locally and systemically derived mediators of periodontal disease, including microbial, host-response, and bone-specific resorptive markers. Although most biomarkers in oral fluids represent inflammatory mediators, several specific collagen degradation and bone turnover-related molecules have emerged as possible measures of periodontal disease activity. Pyridinoline cross-linked carboxyterminal telopeptide (ICTP), for example, has been highly correlated with clinical features of the disease and decreases in response to intervention therapies, and has been shown to possess predictive properties for possible future disease activity. One foreseeable benefit of an oral fluid-based periodontal diagnostic would be identification of highly susceptible individuals prior to overt disease. Timely detection and diagnosis of disease may significantly affect the clinical management of periodontal patients by offering earlier, less invasive, and more cost-effective treatment therapies.
机译:Periodontaldisease是影响软的和硬的支撑结构包围所述齿的细菌引起的慢性炎性疾病。如果不及时治疗,最终的结局是涉及牙齿的牙槽骨丧失和剥落。传统的牙周诊断方法包括临床参数和X光片的评估。虽然高效,这些常规技术中,这本身就仅限历史的角度看,不是当前鉴定,疾病状态可以被确定。在使用口服的液体作为当前疾病状态,治疗监测和预后指标的客观衡量可能的生物样品中的进步已经提高,唾液和其他基于口腔流体技术的前沿。口服流体含有牙周疾病的局部和系统衍生的介质,包括微生物,主机响应和特定骨再吸收标记物。尽管唾液大部分的生物标志物代表炎性介质,几个特定的​​胶原降解和骨代谢有关的分子已经成为牙周疾病活动的可能措施。吡啶啉交联端肽羧基(ICTP),例如,已被高度与疾病的临床特征相关,并响应于介入疗法降低,并已被证明具有用于可能的未来疾病活动预测性质。口服基于流体的牙周诊断的一个可预见的好处将是前明显的疾病高度易感的个体的鉴定。及时发现和诊断疾病可以通过早期,创伤小,且更具成本效益的治疗疗法提供显著影响牙周病患者的临床管理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号